Dose Effects of Recombinant Adenovirus Immunization in Rodents

Abstract

Recombinant adenovirus type 5 (rAd) has been used as a vaccine platform against many infectious diseases and has been shown to be an effective vaccine vector. The dose of the vaccine varies significantly from study to study, making it very difficult to compare immune responses and vaccine efficacy. This study determined the immune correlates induced by serial dilutions of rAd vaccines delivered intramuscularly (IM) and intranasally (IN) to mice and rats. When immunized IM, mice had substantially higher antibody responses at the higher vaccine doses, whereas, the IN immunized mice showed a lower response to the higher rAd vaccine doses. Rats did not show dose-dependent antibody responses to increasing vaccine doses. The IM immunized mice and rats also showed significant dose-dependent T cell responses to the rAd vaccine. However, the T cell immunity plateaued in both mice and rats at 109 and 1010 vp/animal, respectively. Additionally, the highest dose of vaccine in mice and rats did not improve the T cell responses. A final vaccine analysis using a lethal influenza virus challenge showed that despite the differences in the immune responses observed in the mice, the mice had very similar patterns of protection. This indicates that rAd vaccines induced dose-dependent immune responses, especially in IM immunized animals, and that immune correlates are not as predictive of protection as initially thought.

Fractionating a COVID-19 Ad5-vectored vaccine improves virus-specific immunity

“…1B). This result is consistent with the well-reported observation that immunogenicity after adenovirus vaccination is dose dependent ( 12 , 13 ). However, an unexpected effect was observed after the booster immunization 4 weeks later.…”

A novel concept for treatment and vaccination against Covid‐19 with an inhaled chitosan‐coated DNA vaccine encoding a secreted spike protein portion

“…15 There are studies that show a patient's immune response resulting from delivery of a vaccine to the lung may equal or exceeds the immune response created by vaccine injection. 16 It has been proposed that a mucosal immune response may be created via particles of the vaccine material depositing on the upper respiratory tract. 17 A systemic immune response may be created via particles of the vaccine material depositing into the deep lung.…”